SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-236633
Filing Date
2020-09-01
Accepted
2020-09-01 06:07:58
Documents
12
Period of Report
2020-08-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d69240d8k.htm   iXBRL 8-K 21776
  Complete submission text file 0001193125-20-236633.txt   139780

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fprx-20250827.xsd EX-101.SCH 3071
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20250827_lab.xml EX-101.LAB 17372
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20250827_pre.xml EX-101.PRE 10953
5 EXTRACTED XBRL INSTANCE DOCUMENT d69240d8k_htm.xml XML 3258
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS, INC. (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36070 | Film No.: 201153228
SIC: 2834 Pharmaceutical Preparations